<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="347a9376-5865-d57f-e063-6394a90a4ad4"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use IMAAVY safely and effectively. See full prescribing information for IMAAVY.
 <br/>
      <br/>
IMAAVYâ„¢ (nipocalimab-aahu) injection, for intravenous use
 <br/>
Initial U.S. Approval: 2025
</title>
   <effectiveTime value="20250506"/>
   <setId root="8886274c-f2b2-48af-85c1-2f90bfe304b8"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="099091753"/>
            <name>Janssen Biotech, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="038978363"/>
                        <name>Janssen Biotech, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="312670654"/>
                        <name>Vetter Pharma Fertigung GmbH &amp; Co. KG (Ravensburg Mooswiesen)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="316126754"/>
                        <name>Vetter Pharma Fertigung GmbH &amp; Co. KG (Ravensburg Schuetzenstrasse)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="341629292"/>
                        <name>Vetter Pharma Fertigung GmbH &amp; Co. KG (Ravensburg Helmut-Vetter-Strasse)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="344217323"/>
                        <name>Vetter Pharma Fertigung GmbH &amp; Co. KG (Langenargen Eisenbahnstrasse)</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="409612918"/>
                        <name>Janssen Biologics B.V.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="421298354"/>
                        <name>WuXi Biologics Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="429117112"/>
                        <name>Eurofins Biolab Srl</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="483237103"/>
                        <name>Cilag AG</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="544312968"/>
                        <name>WuXi Biologics Biosafety Testing (Suzhou) Co., Ltd.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="544367368"/>
                        <name>WuXi Biologics (Shanghai) Co., Ltd</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" displayName="api manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="986030167"/>
                        <name>Janssen Sciences Ireland UC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="347ab426-84eb-4966-e063-6294a90a6c5c"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250506"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57894-801" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IMAAVY</name>
                        <formCode code="C42899" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION, CONCENTRATE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nipocalimab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F7LTH1E20Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="185"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="87M90CV8NC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NIPOCALIMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="87M90CV8NC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIPOCALIMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="6.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57894-801-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761430" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>colorless to slightly brownish</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57894-800" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>IMAAVY</name>
                        <formCode code="C42899" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION, CONCENTRATE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nipocalimab</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F7LTH1E20Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ARGININE HYDROCHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4QD397987E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="X573657P6P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="AE28F7PNPL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHIONINE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="185"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="87M90CV8NC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>NIPOCALIMAB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="87M90CV8NC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>NIPOCALIMAB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="1.62" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57894-800-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43178" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250429"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="BLA761430" root="2.16.840.1.113883.3.150"/>
                           <code code="C73585" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250429"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48332" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="brown" xsi:type="CE">
                              <originalText>colorless to slightly brownish</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="3405876a-d8da-371b-e063-6294a90a17bd"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>IMAAVY is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. (
 
    <linkHtml href="#S1">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="3405876a-d8db-371b-e063-6294a90a17bd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>See Full Prescribing Information for instructions on dosage, preparation, and administration. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>,
  
     <linkHtml href="#S2.2">2.2</linkHtml>,
  
     <linkHtml href="#S2.3">2.3</linkHtml>)
 
    </item>
                           <item>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of IMAAVY. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>Administer via intravenous infusion only. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                           <item>The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter. (
  
     <linkHtml href="#S2.2">2.2</linkHtml>)
 
    </item>
                           <item>Must be diluted with 0.9% sodium chloride injection prior to administration. (
  
     <linkHtml href="#S2.3">2.3</linkHtml>)
 
    </item>
                           <item>Administer as an intravenous infusion via a 0.2 micron in-line or add-on filter. (
  
     <linkHtml href="#S2.3">2.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3405876a-d8dc-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Vaccination</title>
                     <text>
                        <paragraph>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of IMAAVY. Because IMAAVY causes transient reduction in IgG levels, vaccination with live vaccines is not recommended during treatment with IMAAVY
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="3405876a-d8dd-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>Dilute IMAAVY prior to administration. Administer via intravenous infusion only
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>The recommended initial dosage of IMAAVY is 30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dosage every two weeks thereafter.</paragraph>
                        <paragraph>If a scheduled infusion appointment is missed, the maintenance dosage of IMAAVY should be administered as soon as possible. Resume dosing every two weeks thereafter.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="3405876a-d8de-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation and Administration Instructions</title>
                     <text>
                        <paragraph>Prior to administration, dilute IMAAVY single-dose vials with only 0.9% sodium chloride injection using the instructions below. For patients who weigh 40 kg or more, the total volume to be administered is 250 mL; for patients who are 12 years or older and weigh less than 40 kg, the total volume to be administered is 100 mL
 
  <content styleCode="italics">(see
  
   <linkHtml href="#preparation">Preparation</linkHtml>)
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section ID="preparation">
                           <id root="3405876a-d8df-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation</content>
                              </paragraph>
                              <paragraph>Prepare the solution for infusion using aseptic technique as follows:</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Calculate the dosage (mg), total drug volume (mL) of IMAAVY solution required, and the number of IMAAVY vials needed, based on the patient's current weight
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]
  
   </content>. Each single-dose vial of IMAAVY is at a concentration of 185 mg/mL.
 
  </item>
                                 <item>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Check that the solution in each vial is colorless to slightly brownish, clear to slightly opalescent, and free of visible particles. Do not use if visible particles are present or if the solution is discolored (other than colorless to slightly brownish).</item>
                                 <item>Gently withdraw the calculated volume of IMAAVY from the vial(s). Discard any unused portion of the vials.</item>
                                 <item>Dilute total volume withdrawn of IMAAVY by adding to an infusion container containing 0.9% sodium chloride injection to a final volume of:
  
   <list listType="unordered" styleCode="Circle">
                                       <item>250 mL for patients who weigh 40 kg or more, or</item>
                                       <item>100 mL for patients who weigh less than 40 kg.</item>
                                    </list>Only use infusion containers made of polyolefin, polypropylene, or polyvinylchloride.
 
  </item>
                                 <item>Gently invert the infusion container at least 10 times to mix the solution. Do not shake.</item>
                                 <item>Verify that a uniform solution has been achieved by visual inspection. Do not use if particulate matter or discoloration is present.</item>
                              </list>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="3405876a-d8e0-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Storage Conditions of the Diluted Solution</content>
                                    </paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Administer the diluted IMAAVY solution immediately after preparation.</item>
                                       <item>If the diluted IMAAVY solution is not used immediately:
  
   <list listType="unordered" styleCode="Circle">
                                             <item>Protect from light.</item>
                                             <item>Store refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) for no more than 24 hours.</item>
                                             <item>Do not freeze.</item>
                                             <item>After preparation or removal from the refrigerator, use or discard the IMAAVY diluted solution within 12 hours, including infusion time. During these 12 hours, store under ambient light at 15Â°C to 30Â°C (59Â°F to 86Â°F).</item>
                                          </list>
                                       </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8e1-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If the diluted solution is refrigerated prior to administration, allow to warm to room temperature. Do not use external heat sources to warm IMAAVY.</item>
                                 <item>Administer the diluted solution by intravenous infusion only using an infusion set with an in-line or add-on, sterile, non-pyrogenic, low protein-binding filter made of polyethersulfone or polysulfone (pore size 0.2 micrometer or less). Administration sets must be made of either polybutadiene, polyethylene, polyurethane, polypropylene, or polyvinylchloride.</item>
                                 <item>Do not infuse IMAAVY concomitantly in the same intravenous line with other agents.</item>
                                 <item>Administer IMAAVY infusion intravenously over at least 30 minutes for the initial dose (30 mg/kg) and at least 15 minutes for subsequent doses (15 mg/kg).</item>
                                 <item>If an adverse reaction occurs during administration of IMAAVY, the infusion may be slowed or stopped at the discretion of the healthcare professional.</item>
                                 <item>Monitor the patient for 30 minutes after each infusion for signs or symptoms of an infusion-related or hypersensitivity reaction
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>,
   
    <linkHtml href="#S5.3">5.3)</linkHtml>].
  
   </content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3405876a-d8e2-371b-e063-6294a90a17bd"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: colorless to slightly brownish, clear to slightly opalescent solution available as:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>300 mg/1.62 mL (185 mg/mL) in a single-dose vial</item>
                     <item>1,200 mg/6.5 mL (185 mg/mL) in a single-dose vial</item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Injection: 300 mg/1.62 mL (185 mg/mL) in a single-dose vial (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                           <item>Injection: 1,200 mg/6.5 mL (185 mg/mL) in a single-dose vial (
  
     <linkHtml href="#S3">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="3405876a-d8e3-371b-e063-6294a90a17bd"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or any of the excipients in IMAAVY. Reactions have included anaphylaxis and angioedema
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or to any of the excipients in IMAAVY. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="3405876a-d8e4-371b-e063-6294a90a17bd"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Infections: Delay administration of IMAAVY to patients with an active infection. Monitor for signs and symptoms of infection in patients treated with IMAAVY. If serious infection occurs, administer appropriate treatment and consider withholding IMAAVY until the infection has resolved. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>Hypersensitivity Reactions: Angioedema, anaphylaxis, rash, urticaria, and eczema have occurred in patients treated with IMAAVY. If a hypersensitivity reaction occurs, discontinue the infusion and institute appropriate therapy. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>Infusion-Related Reactions: If a severe infusion-related reaction occurs, discontinue the infusion and initiate appropriate therapy; consider the risks and benefits of readministering. If a mild to moderate infusion-related reaction occurs, may rechallenge with close clinical observation, slower infusion rates, and pre-medication. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="3405876a-d8e5-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Infections</title>
                     <text>
                        <paragraph>IMAAVY may increase the risk of infection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. In Study 1
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>, 42 (43%) out of 98 patients treated with IMAAVY reported 71 events of infection. Across Study 1 (double blind period) and its extension study (open label-period), out of 186 patients treated with IMAAVY, 132 (71%) patients reported 360 events of infection. Serious infections were reported in 7% of patients treated with IMAAVY. Delay IMAAVY administration in patients with an active infection until the infection is resolved. During treatment with IMAAVY, monitor for clinical signs and symptoms of infection. If serious infection occurs, administer appropriate treatment and consider withholding IMAAVY until the infection has resolved.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d8e6-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Latent Viral Infections</content>
                              </paragraph>
                              <paragraph>Patients treated with IMAAVY may be at an increased risk of activation of latent viral infections, such as herpes zoster
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. In the extension period of Study 1, there were 2 patients with serious adverse reactions related to Epstein-Barr virus (EBV) infection, and 1 of these patients had fatal complications. Patients who screened positive for hepatitis were excluded from Study 1. Follow standard vaccination guidelines
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8e7-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Immunization</content>
                              </paragraph>
                              <paragraph>The safety of immunization with live vaccines and the immune response to vaccination during treatment with IMAAVY are unknown. Because IMAAVY causes a reduction in IgG levels, vaccination with live vaccines is not recommended during treatment with IMAAVY.</paragraph>
                              <paragraph>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of treatment with IMAAVY.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3405876a-d8e8-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>In clinical trials, hypersensitivity reactions, including angioedema, anaphylaxis, rash, urticaria, and eczema were observed in patients treated with IMAAVY. In Study 1, hypersensitivity reactions were mild or moderate, occurred within one hour to 2 weeks of administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>. One patient experienced a hypersensitivity reaction (urticaria) that led to treatment discontinuation.

 </paragraph>
                        <paragraph>Management of hypersensitivity reactions depends on the type and severity of the reaction. Monitor the patient during treatment with IMAAVY and for 30 minutes after the administration is complete for clinical signs and symptoms of hypersensitivity reactions
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>. If a hypersensitivity reaction occurs during administration, discontinue IMAAVY infusion and institute appropriate supportive measures if needed. IMAAVY is contraindicated in patients with a history of serious hypersensitivity to nipocalimab or any of the excipients of IMAAVY
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="3405876a-d8e9-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Infusion-Related Reactions</title>
                     <text>
                        <paragraph>In clinical trials, infusion-related reactions, including headache, influenza-like illness, rash, nausea, fatigue, dizziness, chills, and erythema were observed in patients treated with IMAAVY. In Study 1, infusion-related reactions were mild to moderate in severity and occurred within one hour to 2 days of administration
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Monitor patients during treatment with IMAAVY and for 30 minutes after each infusion
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>. If a severe infusion-related reaction occurs, discontinue IMAAVY infusion and initiate appropriate therapy. Consider the risks and benefits of readministering IMAAVY following a severe infusion-related reaction. If a mild to moderate infusion related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medication.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="3405876a-d8ea-371b-e063-6294a90a17bd"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Infections
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Hypersensitivity Reactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Infusion-related Reactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (â‰¥10%) in patients with gMG treated with IMAAVY were respiratory tract infections, peripheral edema, and muscle spasms. (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="3405876a-d8eb-371b-e063-6294a90a17bd"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d8ec-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Adults</content>
                              </paragraph>
                              <paragraph>In Study 1 and its extension study the safety of IMAAVY was evaluated in 186 patients with gMG who received at least one dose of IMAAVY. Of those patients, 168 patients were exposed to IMAAVY every 2 weeks for at least 6 months, and 140 patients were exposed for at least 12 months.</paragraph>
                              <paragraph>In Study 1, 98 adult patients with gMG received IMAAVY 15 mg/kg every two weeks (after 30 mg/kg initial dose)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].
 
  </content>Of these 98 patients, approximately 67% were female, 67% were White, 29% were Asian, and 10% were of Hispanic or Latino ethnicity. The mean age at study entry was 53 years (range 20 to 81).

 </paragraph>
                              <paragraph>Adverse reactions reported in at least 5% of patients treated with IMAAVY and more frequently than placebo, are summarized in Table 1. The most common adverse reactions (reported in at least 10% of patients treated with IMAAVY) were respiratory tract infection, peripheral edema, and muscle spasms.</paragraph>
                              <table width="85%">
                                 <caption>Table 1: Adverse Reactions (â‰¥ 5%) of Patients Treated with IMAAVY and More Frequently than in Placebo in Study 1</caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th styleCode="Rrule">IMAAVY 
     <br/>  N=98 
     <br/>  %
    </th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  N=98 
     <br/>  %
    </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td colspan="3" align="left">Includes the following reported in patients treated with IMAAVY:</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Infection</td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Respiratory tract infection
    
     <footnote ID="K1696">COVID-19 (and other related terms), pneumonia, bronchitis, pneumonia bacteria</footnote>
                                       </td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">13</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Urinary tract infection
    
     <footnote ID="ft1">other related terms</footnote>
                                       </td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Â Â Herpes zoster and Herpes simplex</td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Â Â Oral infection
    
     <footnote ID="K1732">glossitis, oral candidiasis, pericoronitis, pulpitis dental, tooth abscess, tooth infection</footnote>
                                       </td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Peripheral edema</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Muscle spasm</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypersensitivity reaction
    
     <footnote ID="K1767">angioedema, dermatitis atopic, eczema, gingival swelling, rash (and other related terms), urticaria</footnote>
                                       </td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Back pain</td>
                                       <td styleCode="Rrule">8</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pyrexia</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">7</td>
                                       <td styleCode="Rrule">3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Anemia
    
     <footnoteRef IDREF="ft1"/>
                                       </td>
                                       <td styleCode="Rrule">6</td>
                                       <td styleCode="Rrule">4</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">1</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertension</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Insomnia</td>
                                       <td styleCode="Rrule">5</td>
                                       <td styleCode="Rrule">2</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8ed-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infections</content>
                              </paragraph>
                              <paragraph>In Study 1 and its extension study, infections that occurred in patients treated with IMAAVY (n=186) included upper respiratory tract infection (46%), respiratory tract infection (28%; including pneumonia, bronchitis, COVID-19), urinary tract infection (15%), herpes (8%; including herpes simplex, herpes zoster, herpes zoster oticus), influenza (8%), oral infection (8%; including candidiasis and dental infections), and skin infection (7%; including cellulitis). Two (1%) cases of infections (cellulitis and urinary tract infection) led to discontinuation of IMAAVY
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8ee-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hypersensitivity Reactions</content>
                              </paragraph>
                              <paragraph>In Study 1 and its extension study, out of 186 patients treated with IMAAVY, 30 (16%) patients experienced hypersensitivity reactions, which occurred within one hour to two weeks of administration. One patient experienced hypersensitivity reaction (urticaria) that required discontinuation of IMAAVY
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8ef-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infusion-Related Reactions</content>
                              </paragraph>
                              <paragraph>In Study 1 and its extension study, out of 186 patients treated with IMAAVY, 20 (11%) patients experienced infusion-related reactions, which occurred within one hour to 2 days of administration. No patients experienced infusion-related reaction that required discontinuation of IMAAVY
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8f0-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Laboratory Findings</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="3405876a-d8f1-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Lipids</content>
                                    </paragraph>
                                    <paragraph>In Study 1 (N=98), patients treated with IMAAVY had elevations from normal to high of fasting total cholesterol (
 
  <content styleCode="italics">â‰¥</content>240 mg/dL) and LDL cholesterol (
 
  <content styleCode="italics">â‰¥</content>160 mg/dL) (24% and 11% of patients, respectively). In Study 1, these changes from baseline peaked at Week 4, then decreased and plateaued by Week 24 to mean increases of 14 mg/dL and 7 mg/dL, respectively. Five percent of patients treated with IMAAVY had decreases from normal to low (&lt;40 mg/dL of fasting HDL cholesterol).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8f2-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Patients 12 Years of Age and Older</content>
                              </paragraph>
                              <paragraph>In a 24-week, single arm study evaluating the safety of IMAAVY in 7 pediatric patients age 12 to 16 years with gMG who were AChR positive, adverse reactions were consistent with those observed in adult patients with gMG
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3405876a-d8f3-371b-e063-6294a90a17bd"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250430"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. When concomitant long-term use of such medications is essential for patient care, consider discontinuing IMAAVY and using alternative therapies. (
 
    <linkHtml href="#S7">7</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="3405876a-d8f4-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of IMAAVY on Other Drugs</title>
                     <text>
                        <paragraph>Concomitant use of IMAAVY with medications that bind to the human neonatal Fc receptor (FcRn) (e.g., immunoglobulin products, monoclonal antibodies, or antibody derivates containing the human Fc domain of the IgG subclass) may lower systemic exposures and reduce effectiveness of such medications. Closely monitor for reduced effectiveness of medications that bind to the human neonatal Fc receptor. When concomitant long-term use of such medications is essential for patient care, consider discontinuing IMAAVY, and using alternative therapies
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="3405876a-d8f5-371b-e063-6294a90a17bd"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S8.1">
                     <id root="3405876a-d8f6-371b-e063-6294a90a17bd"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d8f7-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are limited data on the use of IMAAVY in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.</paragraph>
                              <paragraph>There was no evidence of direct adverse effects on fetal development following administration of nipocalimab-aahu to pregnant monkeys; however, adverse effects on the placenta were associated with fetal loss at both doses tested
 
  <content styleCode="italics">(see
  
   <linkHtml href="#data">Data</linkHtml>)
 
  </content>.

 </paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background rate of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                              <paragraph>There is a pregnancy safety study for IMAAVY. If IMAAVY is administered during pregnancy, or if a patient becomes pregnant while receiving IMAAVY, healthcare providers should report IMAAVY exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d8f8-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="3405876a-d8f9-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Monoclonal antibodies are increasingly transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Because IMAAVY reduces maternal serum IgG concentration and impedes placental IgG transfer to the fetus, passive immunity in the infant may be reduced for 6 months or more; therefore:</paragraph>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Monitor for the development of serious infection.</item>
                                       <item>Effectiveness of vaccines may be reduced.</item>
                                       <item>Consider the risks and benefits prior to administering live vaccines to infants exposed to IMAAVY
  
   <content styleCode="italics">in utero</content>.
 
  </item>
                                    </list>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="3405876a-d8fa-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>Intravenous administration of nipocalimab-aahu (0, 100, or 300 mg/kg) to pregnant monkeys weekly from the end of organogenesis (gestation day 45) through parturition resulted in placental ischemia, associated with fetal loss and decreased levels of IgG in the offspring at both doses tested. IgG levels in offspring returned to normal levels and no adverse effects on immune function were evident by 6 months after birth. The doses tested are 6 and 20 times the recommended human maintenance dose (15 mg/kg) on a mg/kg basis.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="3405876a-d8fb-371b-e063-6294a90a17bd"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d8fc-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Nipocalimab-aahu is excreted in human colostrum and breastmilk based on limited data from an investigational study of 13 pregnant women administered nipocalimab-aahu during pregnancy where colostrum and breastmilk was assessed in the first 8 days after birth. There are insufficient data on the effect of IMAAVY in the breastfed infant. There are no data on the effect of nipocalimab on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for IMAAVY, and any potential adverse effects on the breastfed infant from IMAAVY, or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="3405876a-d8fd-371b-e063-6294a90a17bd"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of IMAAVY for the treatment of gMG have been established in pediatric patients 12 years of age and older. Use of IMAAVY in pediatric patients for this indication is supported by evidence from an adequate and well-controlled trial in adults with additional pharmacokinetic and safety data in pediatric patients who are 12 years of age and older
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>, and
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Safety and effectiveness of IMAAVY for the treatment of gMG in pediatric patients below the age of 12 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="3405876a-d8fe-371b-e063-6294a90a17bd"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of IMAAVY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger adult patients.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3405876a-d8ff-371b-e063-6294a90a17bd"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Nipocalimab-aahu, a neonatal Fc receptor blocker, is a recombinant human immunoglobulin G1 lambda (IgG1Î») monoclonal antibody, expressed in a genetically engineered Chinese hamster ovary cell line. Nipocalimab-aahu has an aglycosylated Fc region, therefore it lacks effector functions. Nipocalimab-aahu has an approximate molecular weight of 142 kilodaltons (kDa).</paragraph>
                  <paragraph>IMAAVYâ„¢ (nipocalimab-aahu) injection is a sterile, preservative-free, colorless to slightly brownish, clear to slightly opalescent solution, supplied in a single-dose vial for intravenous infusion after dilution.</paragraph>
                  <paragraph>Each single-dose vial contains either 300 mg/1.62 mL or 1,200 mg/6.5 mL of nipocalimab-aahu at a concentration of 185 mg/mL. In addition, each mL of solution contains arginine hydrochloride (25.35 mg), histidine (0.77 mg), L-histidine monohydrochloride monohydrate (1.07 mg), methionine (1.0 mg), polysorbate 80 (0.60 mg), sucrose (64.3 mg), and water for injection, USP, at a pH of 6.0.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="3405876a-d900-371b-e063-6294a90a17bd"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S12.1">
                     <id root="3405876a-d901-371b-e063-6294a90a17bd"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Nipocalimab-aahu is a human IgG1 monoclonal antibody that binds to neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG levels.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="3405876a-d902-371b-e063-6294a90a17bd"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>In Study 1
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14">Clinical Studies (14)</linkHtml>],
 
  </content>the pharmacological effect of nipocalimab-aahu was assessed by measuring the decrease in serum IgG levels and anti-AChR and anti-MuSK autoantibody levels. In patients positive for AChR and MuSK autoantibodies who were treated with IMAAVY, there was a reduction in AChR and MuSK autoantibodies relative to baseline. Decreases in total IgG levels followed a similar pattern. A similar reduction in AChR autoantibodies was observed in adolescent patients with gMG compared to adults.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="3405fd50-5985-891a-e063-6294a90afda9"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Nipocalimab exhibits nonlinear pharmacokinetics. Following a single intravenous infusion of IMAAVY at doses ranging from 0.3 to 60 mg/kg (4 times the recommended maintenance dosage) in healthy participants, C 
  <sub>max</sub> of nipocalimab-aahu increased in a dose-proportional manner while AUC increased in a greater than dose-proportional manner.
 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d904-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Mean volume of distribution of nipocalimab is 2.67 L.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d905-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Metabolism</content>
                              </paragraph>
                              <paragraph>Nipocalimab is expected to be degraded by proteolytic enzymes into small peptides and amino acids.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d906-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Nipocalimab exhibits concentration-dependent pharmacokinetics. After a single intravenous administration of 15 mg/kg nipocalimab-aahu, the mean clearance is 0.0627 L/h and half-life is 29.3 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d907-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="3405876a-d908-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Age, Sex, and Race</content>
                                    </paragraph>
                                    <paragraph>The pharmacokinetics of nipocalimab were not affected by age, sex, or race based on a population pharmacokinetics analysis.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3405876a-d909-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatric Patients</content>
                                    </paragraph>
                                    <paragraph>Following the recommended intravenous doses of IMAAVY in adolescent patients 12 to 16 years of age with gMG (N=7), the observed steady-state serum nipocalimab-aahu concentrations were within the range of those observed for adult patients with gMG
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section ID="id_link_3405f848-0103-8e49-e063-6294a90a67c3">
                                 <id root="3405f848-0102-8e49-e063-6294a90a67c3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>No dedicated pharmacokinetic study has been conducted in patients with renal impairment. Renal impairment is not expected to affect the pharmacokinetics of nipocalimab. Based on a population pharmacokinetic analysis, which included healthy volunteers and patients with gMG with mild to moderate renal impairment, renal function (estimated glomerular filtration rate [eGFR] 30â€“89 mL/min/1.73 m
  <sup>2</sup>) had no clinically significant effect on nipocalimab-aahu clearance. No dose adjustment is required in patients with renal impairment.
 </paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3405876a-d90b-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>No dedicated pharmacokinetic study has been performed in patients with hepatic impairment. Nipocalimab is not metabolized by cytochrome P450 enzymes, and hepatic impairment is not expected to affect the pharmacokinetics of nipocalimab. Based on a population pharmacokinetic analysis, which included healthy volunteers and patients with gMG with mild to moderate hepatic impairment, there was no clinically significant effect on nipocalimab-aahu clearance. No dose adjustment is required in patients with hepatic impairment.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d90c-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions with Other Drugs or Biological Products</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                           <component>
                              <section>
                                 <id root="3405876a-d90d-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">IgG-Based Monoclonal Antibodies</content>
                                    </paragraph>
                                    <paragraph>Nipocalimab decreases concentrations of compounds that bind to the human FcRn, including IgG based monoclonal antibodies.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3405876a-d90e-371b-e063-6294a90a17bd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cytochrome P450 Enzymes</content>
                                    </paragraph>
                                    <paragraph>Nipocalimab is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.</paragraph>
                                 </text>
                                 <effectiveTime value="20250430"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="3405876a-d90f-371b-e063-6294a90a17bd"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6 Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of nipocalimab-aahu or of other nipocalimab products.</paragraph>
                        <paragraph>In clinical trials, antibodies to nipocalimab-aahu were detected in 49/102 (48%) adult and pediatric patients 12 years of age and older during 24-week treatment period.</paragraph>
                        <paragraph>Out of the 49 patients who were positive for antibodies to nipocalimab-aahu, 19 (38.8%) patients had neutralizing antibodies to nipocalimab-aahu. There was no identified clinically relevant effect of antibodies, including neutralizing antibodies, to nipocalimab-aahu on the pharmacokinetics, pharmacodynamics, safety, or effectiveness of IMAAVY.</paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3405876a-d910-371b-e063-6294a90a17bd"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section ID="S13.1">
                     <id root="3405876a-d911-371b-e063-6294a90a17bd"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d912-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Studies to assess the carcinogenic potential of nipocalimab-aahu have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d913-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Studies to assess the genotoxic potential of nipocalimab-aahu have not been conducted.â€¯As an antibody, nipocalimab-aahu is not expected to interact directly with DNA.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d914-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Once or twice weekly intravenous administration of nipocalimab-aahu (0, 20, 50, 100, or 300 mg/kg) to male and female monkeys for 26 weeks resulted in no adverse effects on reproductive organs upon histopathological examination. The highest dose tested was 20 times the recommended human maintenance dose (15 mg/kg) on a mg/kg basis.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="3405fdc0-fe81-6ba9-e063-6294a90ac8dc"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of IMAAVY for the treatment of gMG in adults who are anti-AChR or anti-MuSK antibody positive was established in a 24-week, multicenter, randomized, double-blind, placebo-controlled study (Study 1; NCT04951622). Patients were treated with IMAAVY with the recommended dosage regimen 
  <content styleCode="italics">[see 
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>] 
  </content>.
 </paragraph>
                  <paragraph>Study 1 enrolled patients with gMG who met the following criteria:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Myasthenia Gravis Foundation of America (MGFA) Clinical Classification Class II to IV</item>
                     <item>Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of at least 6</item>
                     <item>On stable dose of standard of care MG therapy prior to baseline that included acetylcholinesterase (AChE) inhibitors, steroids or non-steroidal immunosuppressive therapies (NSISTs), either in combination or alone.</item>
                  </list>
                  <paragraph>In Study 1, a total of 196 patients were randomized 1:1 to receive IMAAVY (n=98) or placebo (n=98). Baseline characteristics were similar between treatment groups. For the primary efficacy analysis population (n=153), patients had a median age of 52 years at screening (range 20 to 81 years) and a median time since diagnosis of 6 years. Sixty percent of patients were female; 63% were White; 32% were Asian; 1% were Black or African-American; and &lt;1% were American Indian or Alaskan Native. At baseline, median MG-ADL total score was 9, and median Quantitative Myasthenia Gravis (QMG) total score was 15. Eighty-eight percent (n=134) of patients were positive for AChR antibodies and 10% (n=16) were positive for MuSK antibodies.</paragraph>
                  <paragraph>At baseline, in each group, 85% of patients received AChE inhibitors, 66% of patients received steroids, and 54% of patients received NSISTs at stable doses.</paragraph>
                  <paragraph>The efficacy of IMAAVY was measured using the MG-ADL scale, which assesses the impact of gMG on daily functions of 8 signs and symptoms that are typically affected in gMG. Each item is assessed on a 4-point scale, where a score of 0 represents normal function and a score of 3 represents loss of ability to perform that function. A total score ranges from 0 to 24, with the higher scores indicating more impairment.</paragraph>
                  <paragraph>The primary efficacy endpoint was the comparison of the mean change from baseline to Weeks 22, 23, and 24 between treatment groups in the MG-ADL total score. A statistically significant difference favoring IMAAVY was observed in MG-ADL total score change from baseline (p=0.002; see 
  <linkHtml href="#Tb2">Table 2</linkHtml> and 
  <linkHtml href="#fig1">Figure 1</linkHtml>).
 </paragraph>
                  <paragraph>The efficacy of IMAAVY was also measured using the QMG total score, which is a 13-item categorial grading system that assesses muscle weakness. Each item is assessed on a 4 -point scale, where a score of 0 represents no weakness, and a score of 3 represents severe weakness. A total possible score ranges from 0 to 39, where higher scores indicate more severe impairment.</paragraph>
                  <paragraph>The secondary endpoint was the comparison of the mean change from baseline to Weeks 22 and 24 between treatment groups in the QMG total score. A statistically significant difference favoring IMAAVY was observed in the QMG total score change from baseline (p&lt;0.001; see 
  <linkHtml href="#Tb2">Table 2</linkHtml>).
 </paragraph>
                  <paragraph>The results are presented shown in Table 2.</paragraph>
                  <table width="85%" ID="Tb2">
                     <caption>Table 2: Least Squares Mean Change from Baseline to Week 24 in MG-ADL and QMG Total Scores in Study 1</caption>
                     <colgroup>
                        <col align="left" valign="top" width="30%"/>
                        <col align="center" valign="top" width="20%"/>
                        <col align="center" valign="top" width="15%"/>
                        <col align="center" valign="top" width="25%"/>
                        <col align="center" valign="top" width="10%"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th align="center" styleCode="Lrule Rrule" valign="bottom">Efficacy Endpoints</th>
                           <th styleCode="Rrule">IMAAVY
     <br/>
			N = 77
     <br/>
			LS Mean (SE)
    </th>
                           <th styleCode="Rrule">Placebo
     <br/>
			N = 76
     <br/>
			LS Mean (SE)
    </th>
                           <th styleCode="Rrule">IMAAVY Change Relative to Placebo
     <br/>
			LS Mean Difference (95% CI)
    </th>
                           <th styleCode="Rrule" valign="bottom">p-value</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="5">Key: CI=confidence interval; MG-ADL = Myasthenia Gravis â€“ Activities of Daily Living; QMG = Quantitative Myasthenia Gravis; LS mean = Least squares mean; SE = standard error</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Primary Endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">MG-ADL Total Score 
     <footnote ID="K2798">Mean change from baseline over weeks 22, 23, and 24</footnote>
                           </td>
                           <td styleCode="Rrule">-4.7 (0.33)</td>
                           <td styleCode="Rrule">-3.3 (0.34)</td>
                           <td styleCode="Rrule">-1.5 (-2.4, -0.5)</td>
                           <td styleCode="Rrule">0.002</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Secondary Endpoint</content>
                           </td>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                           <td styleCode="Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">QMG
     <br/>
			Total Score 
     <footnote ID="K2833">Mean change from baseline over weeks 22 and 24</footnote>
                           </td>
                           <td styleCode="Rrule" valign="bottom">-4.9 (0.5)</td>
                           <td styleCode="Rrule" valign="bottom">-2.1 (0.5)</td>
                           <td styleCode="Rrule" valign="bottom">-2.8 (-4.2, -1.4)</td>
                           <td styleCode="Rrule" valign="bottom">&lt;0.001</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Figure 1 shows the mean change from baseline to Week 24 in MG-ADL total score in Study 1, and Figure 2 shows the mean change from baseline to Week 24 in QMG total score in Study 1.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 1: Least Squares Mean Change from Baseline in MG-ADL Total Score Over 24 Weeks in Study 1</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>LS = least squares, SE = standard error, MG-ADL = Myasthenia Gravis Activities of Daily Living</paragraph>
                  <paragraph>
                     <content styleCode="bold">Figure 2: Least Squares Mean Change from Baseline in QMG Total Score Over 24 Weeks in Study 1</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>LS = least squares, SE = standard error, QMG = Quantitative Myasthenia Gravis.</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="imaavy-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="imaavy-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="3405876a-d916-371b-e063-6294a90a17bd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="3405876a-d917-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">How Supplied</content>
                        </paragraph>
                        <paragraph>IMAAVYâ„¢ (nipocalimab-aahu) injection is a sterile, preservative-free, colorless to slightly brownish, clear to slightly opalescent solution for intravenous use after dilution.</paragraph>
                        <paragraph>IMAAVY is supplied in cartons containing a single-dose vial per carton as:</paragraph>
                        <table width="80%" styleCode="Noautorules">
                           <col width="60%" align="left" valign="top"/>
                           <col width="40%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>300 mg/1.62 mL (185 mg/mL)</item>
                                    </list>
                                 </td>
                                 <td>NDC 57894-800-01</td>
                              </tr>
                              <tr>
                                 <td>
                                    <list listType="unordered" styleCode="Disc">
                                       <item>1,200 mg/6.5 mL (185 mg/mL)</item>
                                    </list>
                                 </td>
                                 <td>NDC 57894-801-01</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3405876a-d918-371b-e063-6294a90a17bd"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                     <component>
                        <section>
                           <id root="3405876a-d919-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Unopened Vials</content>
                              </paragraph>
                              <paragraph>Store vials refrigerated at 2Â°C to 8Â°C (36Â°F to 46Â°F) in the original carton to protect from light until the time of use. Do not freeze. Do not shake.</paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3405876a-d91a-371b-e063-6294a90a17bd"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Diluted Solution</content>
                              </paragraph>
                              <paragraph>For storage of the diluted IMAAVY solution,
 
  <content styleCode="italics">see
  
   <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>
                                 </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20250430"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="3405876a-d91b-371b-e063-6294a90a17bd"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <section>
                     <id root="3405876a-d91c-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infections</content>
                        </paragraph>
                        <paragraph>Instruct patients to communicate any history of infections to the healthcare provider and to contact their healthcare provider if they develop any symptoms of an infection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3405876a-d91d-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration of Vaccines</content>
                        </paragraph>
                        <paragraph>Advise patients to complete all age-appropriate vaccines according to immunization guidelines prior to initiation of treatment with IMAAVY. Administration of live vaccines is not recommended during treatment with IMAAVY. Instruct patients to inform the healthcare provider that they are being treated with IMAAVY prior to a potential vaccination
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3405876a-d91e-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hypersensitivity Reactions</content>
                        </paragraph>
                        <paragraph>Inform patients that hypersensitivity reactions, including anaphylaxis, angioedema, rash, urticaria, and eczema have occurred in patients treated with IMAAVY. Inform patients about the signs and symptoms of hypersensitivity reactions. Advise patients to contact their healthcare provider immediately if these occur
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3405876a-d91f-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infusion-Related Reactions</content>
                        </paragraph>
                        <paragraph>Advise patients that administration of IMAAVY may result in infusion-related reactions
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3405876a-d920-371b-e063-6294a90a17bd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients that there is a pregnancy safety study that monitors pregnancy outcomes in women exposed to IMAAVY during pregnancy, and they can be enrolled by calling 1-800-526-7736 or www.IMAAVY.com
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250430"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3405876a-d921-371b-e063-6294a90a17bd"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by: 
  <br/>  Janssen Biotech, Inc. 
  <br/>  Horsham, PA 19044, USA 
  <br/>  U.S. License No. 1864
 </paragraph>
                  <paragraph>For patent information: www.janssenpatents.com</paragraph>
                  <paragraph>Â© 2025 Janssen Pharmaceutical Companies</paragraph>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="id_link_340595f3-f277-ce82-e063-6394a90a38f0">
               <id root="340595f3-f276-ce82-e063-6394a90a38f0"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%" ID="patient">
                     <colgroup>
                        <col align="left" valign="middle" width="3%"/>
                        <col align="left" valign="middle" width="50%"/>
                        <col align="left" valign="middle" width="22%"/>
                        <col align="left" valign="middle" width="25%"/>
                     </colgroup>
                     <thead>
                        <tr>
                           <th align="center" colspan="4" styleCode="Lrule Rrule">PATIENT INFORMATION
     <br/>
			IMAAVYâ„¢ [im-AH-vee]
     <br/>
			(nipocalimab-aahu)
     <br/>
			injection, for intravenous use
    </th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td align="left" colspan="3">This Patient Information has been approved by the U.S. Food and Drug Administration</td>
                           <td align="right">Issued: 4/2025</td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is IMAAVY?</content>
                              <br/>
			IMAAVY is a prescription medicine used to treat adults and children 12 years of age and older with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
     <br/>
			It is not known if IMAAVY is safe and effective in children under 12 years of age.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Do not receive IMAAVY if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have a history of a severe allergic reactions to nipocalimab or any of the ingredients in IMAAVY. Reactions have included angioedema and anaphylaxis. See the end of this Patient Information leaflet for a complete list of ingredients in IMAAVY.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before receiving IMAAVY, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>ever had an allergic reaction to IMAAVY. Ask your healthcare provider if you are not sure.</item>
                                 <item>have or have had any recent infections or have any symptoms of infection.</item>
                                 <item>have recently received or are scheduled to receive an immunization (vaccine). People who are being treated with IMAAVY should not receive live vaccines.</item>
                                 <item>are pregnant or plan to become pregnant. It is not known whether IMAAVY will harm your unborn baby.
				
       <list listType="unordered" styleCode="Circle">
                                       <item>
                                          <content styleCode="bold">Pregnancy Safety Study.</content> There is a pregnancy safety study for IMAAVY if IMAAVY is given during pregnancy or you become pregnant while receiving IMAAVY. Your healthcare provider should report IMAAVY exposure by contacting Janssen at 1-800-526-7736 or www.IMAAVY.com.
        </item>
                                    </list>
                                 </item>
                                 <item>IMAAVY can pass into your breastmilk and it is not known whether IMAAVY will harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive IMAAVY.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">How will I receive IMAAVY?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>IMAAVY will be given to you by your healthcare provider through a needle placed into your vein (intravenous [IV] infusion).</item>
                                 <item>You will receive a starting dose of IMAAVY infusion lasting at least 30 minutes. Two weeks later you will receive your next dose of IMAAVY infusion lasting at least 15 minutes. Your following doses will be given every two weeks.</item>
                                 <item>If you have a reaction during your IMAAVY infusion, your healthcare provider may decide to give IMAAVY more slowly or to stop your infusion.</item>
                                 <item>If you miss a scheduled IMAAVY infusion, you should receive your next dose as soon as possible.</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while receiving IMAAVY?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>You should not be given live vaccines while receiving IMAAVY.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of IMAAVY?
      <br/>
			IMAAVY may cause serious side effects, including:
     </content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infections.</content> Infections are a common side effect of IMAAVY that can be serious. Receiving IMAAVY may increase your risk of infection. Tell your healthcare provider right away if you have any of the following symptoms of infection:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever</item>
                                 <item>chills</item>
                                 <item>shivering</item>
                                 <item>cough</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>sore throat</item>
                                 <item>fever blisters</item>
                                 <item>burning when you urinate</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Allergic (hypersensitivity) reactions.</content> Allergic reactions may happen during or up to a few weeks after your IMAAVY infusion. Get emergency medical help right away if you get any of these symptoms during or after your IMAAVY infusion, which may be part of a serious allergic reaction:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>swelling of your face, lips, mouth, tongue, or throat</item>
                                 <item>difficulty swallowing or breathing</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>itchy rash (hives)</item>
                                 <item>chest pain or tightness</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infusion-related reactions.</content> Tell your healthcare provider right away if you get any of the following symptoms during or a few days after your infusion of IMAAVY:
      </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="Circle">
                                 <item>headache</item>
                                 <item>rash</item>
                                 <item>nausea</item>
                                 <item>fatigue</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="Circle">
                                 <item>dizziness</item>
                                 <item>chills</item>
                                 <item>flu-like symptoms</item>
                                 <item>redness of skin</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects in people with gMG treated with IMAAVY include:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>infection in parts of your body that you use for breathing (respiratory tract infection)</item>
                                 <item>swelling in your hands, ankles, or feet (peripheral edema)</item>
                                 <item>muscle spasms</item>
                              </list>
			These are not all of the possible side effects of IMAAVY.
     <br/>
			Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of IMAAVY.</content>
                              <br/>
			Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.
     <br/>
			You can ask your pharmacist or healthcare provider for information about IMAAVY that is written for health professionals.
    </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="4" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients of IMAAVY?
      <br/>
			Active ingredient
     </content>: nipocalimab-aahu
     <br/>
                              <content styleCode="bold">Inactive ingredients</content>: arginine hydrochloride, histidine, L-histidine monohydrochloride monohydrate, methionine, polysorbate 80, sucrose, and water for injection.
    </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode="Lrule Rrule">Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044, USA
     <br/>
			U.S. License Number 1864
     <br/>
			For patent information: www.janssenpatents.com
     <br/>
			Â© 2025 Janssen Pharmaceutical Companies
     <br/>
			For more information, call 1-800-526-7736 or go to www.IMAAVY.com
    </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250430"/>
            </section>
         </component>
         <component>
            <section ID="id_link_34062e63-c12b-0e08-e063-6394a90aa42b">
               <id root="34063a49-b4c5-119a-e063-6394a90ac680"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 300 mg / 1.62 mL Vial Box</title>
               <text>
                  <paragraph>NDC 57894-800-01</paragraph>
                  <paragraph>imaavyâ„¢
  <br/>
(nipocalimab-aahu)
  <br/>
Injection
 </paragraph>
                  <paragraph>300 mg / 1.62 mL
  <br/>
(185 mg / mL)
 </paragraph>
                  <paragraph>For Intravenous Infusion
  <br/>
After Dilution
 </paragraph>
                  <paragraph>Rx only
  <br/>
One single-dose vial.
  <br/>
Discard unused portion.
 </paragraph>
                  <paragraph>Johnson
  <br/>
&amp; Johnson
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_34063404-c42e-a4ca-e063-6294a90abdf7"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_34063404-c42e-a4ca-e063-6294a90abdf7">
                     <text>300mg</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="300mg Box.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="id_link_34063404-c430-a4ca-e063-6294a90abdf7">
               <id root="347a8fd0-2b9d-31fc-e063-6294a90a1879"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1,200 mg / 6.5 mL Vial Box</title>
               <text>
                  <paragraph>NDC 57894-801-01</paragraph>
                  <paragraph>imaavyâ„¢
  <br/>
(nipocalimab-aahu)
  <br/>
Injection
 </paragraph>
                  <paragraph>1,200 mg / 6.5 mL
  <br/>
(185 mg / mL)
 </paragraph>
                  <paragraph>For Intravenous Infusion
  <br/>
After Dilution
 </paragraph>
                  <paragraph>Rx only
  <br/>
One single-dose vial.
  <br/>
Discard unused portion.
 </paragraph>
                  <paragraph>Johnson
  <br/>
&amp; Johnson
 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_34063f46-97ff-ac0d-e063-6294a90abf7e"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250430"/>
               <component>
                  <observationMedia ID="img_34063f46-97ff-ac0d-e063-6294a90abf7e">
                     <text>1200mg </text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="1200 mg Box.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>